Publication:
Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes

dc.contributor.authorBogas, Gador
dc.contributor.authorMayorga, Cristobalina
dc.contributor.authorMartín-Serrano, Ángela
dc.contributor.authorFernández-Santamaría, Rubén
dc.contributor.authorJiménez-Sánchez, Isabel M.
dc.contributor.authorAriza, Adriana
dc.contributor.authorBarrionuevo, Esther
dc.contributor.authorPosadas, Teresa
dc.contributor.authorSalas, María
dc.contributor.authorFernández, Tahía Diana
dc.contributor.authorTorres, María José
dc.contributor.authorMontañez, María Isabel
dc.contributor.authoraffiliation[Bogas,G; Mayorga,G; Martín-Serrano,A; Fernández-Santamaría,R; Jiménez-Sánchez,IM; Ariza,A; Barrionuevo,E; Posadas,T; Salas,M; Fernández,TD; Torres,MJ; Montañez,MI] Allergy Research Group, Instituto de Investigación Biomédica de Málaga- IBIMA, Hospital Civil, Málaga, Spain. [Bogas,G; Mayorga,G; Barrionuevo,E; Posadas,T; Salas,M; Torres,MJ] Allergy Unit, Hospital Regional Universitario de Málaga, Hospital Civil, Málaga, Spain. [Mayorga,G; Martín-Serrano,A; Jiménez-Sánchez,IM; Torres,MJ; Montañez,MI] Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain. [Fernández,TD] Departamento de Biología Celular, Genética y Fisiología, Universidad de Málaga, Málaga, Spain. [Torres,MJ] Departamento de Medicina, Universidad de Málaga, Facultad de Medicina, Málaga, Spain.
dc.date.accessioned2024-02-12T19:48:15Z
dc.date.available2024-02-12T19:48:15Z
dc.date.issued2020-12-04
dc.description.abstractBackground: Analysis of cross-reactivity is necessary for prescribing safe cephalosporins for penicillin allergic patients. Amoxicillin (AX) is the betalactam most often involved in immediate hypersensitivity reactions (IHRs), and cefadroxil (CX) the most likely cephalosporin to cross-react with AX, since they share the same R1 side chain, unlike cefuroxime (CO), with a structurally different R1. We aimed to analyse cross-reactivity with CX and CO in patients with confirmed IHRs to AX, including sIgE recognition to AX, CX, CO, and novel synthetic determinants of CX. Methods: Fifty-four patients with confirmed IHRs to AX based on skin test (ST) and/or drug provocation test (DPT) were included. Serum sIgE to AX and benzylpenicillin was determined by Radioallergosorbent test (RAST). Two potential determinants of CX, involving intact or modified R1 structure, with open betalactam ring, were synthesised and sIgE evaluated by RAST inhibition assay. Results: Tolerance to CX (Group A) was observed in 64.8% cases and cross-reactivity in 35.2% cases (Group B). Cross-reactivity with CO was only found in 1.8% cases from Group B. ST to CX showed a negative predictive value of 94.6%. RAST inhibition assays showed higher recognition to CX as well as to both synthetic determinants (66% of positive cases) in Group B. Conclusions: Cross-reactivity with CX in AX allergic patients is 35%, being ST not enough for prediction. R1, although critical for recognition, is not the unique factor. The synthetic determinants of CX, 1-(HOPhG-Ser-Bu) and 2-(pyrazinone) are promising tools for determining in vitro cross-reactivity to CX in AX allergic patients. Background: Betalactams (BLs) are the drugs most frequently involved in immediate (IgE-mediated) hypersensitivity reactions (IHRs) [1,2,3], which could be explained by their ability to act as haptens due to their high chemical reactivity against proteins [4, 5]. BL chemical structure is formed by a 4-membered ring (the so-called BL ring) that in penicillins is fused to a 5-membered thiazolidine ring, and in cephalosporins to a 6-membered dihydrothiazine ring (Fig. 1). These drugs have a side chain (R1) bound to the BL ring; besides, cephalosporins have a second side chain (R2) bound to the dihydrothiazine ring, whose chemical structures distinguish the different compounds [6, 7].
dc.description.sponsorshipThe present study has been supported by the Institute of Health ‘‘Carlos III’’ (ISCIII) of MINECO (Grants cofunded by ERDF: ‘‘Una manera de hacer Europa’’: Grant ns. PI12/02529, PI15/01206, CP15/00103, PI17/01237, PI18/00095, RETIC ARADYAL RD16/0006/0001, Euronanomed Program AC19/00082; Andalusian Regional Ministry of Economy and Knowledge (Grants cofunded by ERDF: ‘‘Andalucía se mueve con Europa’’: Grant No. CTS-06603); Andalusian Regional Ministry of Health (Grant Nos. PI-0699–2011, PI-0179–2014, PE-0172–2018 cofunded by ERDF); and ‘‘Premio UNICAJA a la innovación en biomedicina y salud.’’ C.M. holds ‘Nicolas Monardes’ research contract by Andalusian Regional Ministry Health (Grant No. C-0044–2012 SAS2013). G.B. holds a “Juan Rodes” Grant (JR18/00054), M.I.M. holds a ‘‘Miguel Servet I’’ Grant (CP15/00103), and A.A. holds a ‘‘Sara Borrell’’ Grant (CD17/0146), all by ISCIII of MINECO (grants cofunded by European Social Fund: ‘‘El FSE invierte en futuro’’). R.F.S. holds a predoctoral Grant (PE-0172–2018) cofunded by ERDF.
dc.identifier.doi10.1186/s13601-020-00368-1
dc.identifier.e-issn2045-7022es_ES
dc.identifier.journalClinical and Translational Allergyes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/3574
dc.identifier.pubmedID33292516es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18169
dc.language.isoeng
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://ctajournal.biomedcentral.com/articles/10.1186/s13601-020-00368-1es
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAmoxicillin
dc.subjectBetalactam
dc.subjectCephalosporin
dc.subjectCross-reactivity
dc.subjectDrug allergy
dc.subjectAntigenic determinant
dc.subjectSpecific IgE
dc.subjectAmoxicilina
dc.subjectBeta-lactamas
dc.subjectCefalosporinas
dc.subjectHipersensibilidad a las Drogas
dc.subjectReacciones cruzadas
dc.subjectEpítopos
dc.subjectInmunoglobulina E
dc.subject.meshAmoxicillin
dc.subject.meshCephalosporins
dc.subject.meshbeta-Lactams
dc.subject.meshCross Reactions
dc.subject.meshDrug Hypersensitivity
dc.subject.meshEpitopes
dc.subject.meshImmunoglobulin E
dc.subject.meshHumans
dc.titlePenicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files